



**23500-5—
2021**

1 « -
» (« ») « »
(« ») -
4
2 011 « ,
»
3 -
21 2021 . 1195-
4 23500-5:2019 «
5. -
» (ISO 23500-5:2019 «Preparation
and quality management of fluids for haemodialysis and related therapies — Part 5: Quality of dialysis fluid for
haemodialysis and related therapies», IDT).

-
,
5
26
29 2015 . № 162- «
(1
) « ,
— «
() ».
».
,
—
(www.rst.gov.ru)

1	1
2	1
3	2
4	2
4.1	2
4.2	3
5	3
5.1	3
5.2	3
()	5
8 ()	8
()	12
	13

—

—

—

—

[-]

$$(\quad):$$

ISO 23500-1. Preparation and quality management of fluids for haemodialysis and related therapies —

Part 1: General requirements (

—

1.)

ISO 23500-3, Preparation and quality management of fluids for haemodialysis and related therapies —

Part 3: Quality of water for haemodialysis and related therapies (

3.

)

ISO 23500-4. Preparation and quality management of fluids for haemodialysis and related therapies —

Part 4: Concentrates for haemodialysis and related therapies (

4.

—

)

3

23500-1.

- :
- : <https://www.iso.org/obp>;
- : <http://www.electropedia.org/>.

4

4.1

4.1.1

4.1.2

100 / (5)
0.5 / (5).

50 %

4.1.3

0.1 / (5)
0,03 / (5).

4.1.4

4.2

23500-3.
23500-4.

0.1 / .

5

5.1

10

4

< 10 °C

24

5.2

1.

0.1 0.3 ;

1

10 1000

Reasoner 2A(R2A) (TSA)

[6]. [7]. 2016 . (8)

& 50 / R2A

TSA 1. (TGEA), 17 ' 23

7 , TSA [9].

Mattais 2 50 / TSA 35 37 ' 48 (= 0.001).

2 50 / [8].

1 —		
(TGEA)	17' 23 '	7
Reasoner 2 (R2A)	17- 23 '	7
(TSA) ^a	35 * 37 '	48
TSA		

Limulus amoebccyte lysate (LAL)

()

.1

(. .) [10]. [11]. [12]. [13].

[14]. [15].

[16]. [17].

. Vanhotder

in vitro 10^3 10^4 / (Pseudomonas) [18].

[19]—[25].

[26].

[27].

[28]. [29].

(JSDT)

> 0.100 / [30]. [31].

2 / AAMI 2001

$0,25$ / 13959 2009 . 0.25 /

0.5 / .

Limulus.

2^{-}

[14]. [17]. [25]. [32]. [44].

[45]. »>

0.03 / [46]. 0.1 /

, , , -

, , . -

, , 7 ,

, , -

, , , -

, , , -

[47]. (20 100). -

, , -

, , -

.2

23500-3:2019 23500-4:2019. -

, , -

, , -

, , -

, , -

(SMA). [11]. -

(TSA) — -

, , -

, , 1. -

[8]. [46]. [48]. -

Reasoner 2 (R2A) (TSA) -

[49]. 2016 , -

250 / . R2A TSA , -

[8]. arap(TGEA). 17' 23 * 7 , -

TSA[6]. Maltais . [8] TSA 2 50 / . -

TSA 35 °C 37 * -

48 (= 0.001). , (TGEA TSA) -

2 50 / . , , -

, , , , , -

， ， ， -
， ， -
， ， -
-
，
(1000)
，
-
-
：
[51]. [52]. [53].
[50]. (. .
)， ， ， -
-
(). 17 * 23 *
168 (7).
， ， -
.

()

.1 —

3

-

	. / 6
	0,01
1	0.1
	0.1
	0.2
	0.005
(N)	2
	100
	0.1
	2 (0.05 /)
	4 (0,15 /)
	8 /)
	70 (3.0 /)
8 , , , -	
1 () .	-
() .	-
0.1 / .	-
2. , , -	

.2 —

	, /
	0.006
	0.005
	0.1

. 2

	, /
	0.0004
	0.001
	0.014
	0.0002
	0.09
	0.005
	0.002
.1 —	, ,
.2.	, ,

, .1 .2.
ISO.
-
0.1 / .

		,
-	- (-)	17294-2:2016 .#3113
-	- (-)	ISO 17294-2:2016 .#200.9
-	- (-)	17294-2:2016 , #3114
-	- (-)	17294-2:2016 .#3113
-	- (-)	ISO 17294-2:2016 .#200.9
-	- (-)	17294-2:2016 .#3113
-	, (-) , (-) , -	17294-2:2016 .#3500- D .#3111
DPD (N- - -) -	DPD (N- - -) - , (/)	. #4500-0 F .#4500-0 G

	- (-)	17294-2:2016 #3113
	- (-),	17294-2:2016 #3111 #3500- D
	2-(4-)-1.8- 3.6- (SPADNS)	ISO 10304-12007 ISO 10359-1:1992 #4500-F* #4500-F* D
	- (-)	17294-2:2016 #3113
	- (-),	17294-2:2016 #3111 #300.7:1986
	(-)	#3112
	, - , - , -	10304-1:2007 7890-3:1988 #4500-NO ₃
	- (-), , -	17294-2:2016 #3111 #3500- D #3500-
	- (-), ()	17294-2:2016 #3114 #3113
	- (-)	17294-2:2016 #3113
	- (-), , -	17294-2:2016 #3111 #3500-Na D
	-	10304-1:2007 #4500-SO ₄ ^{2*}

		,
	- - (-)	13017294-2:2016 . #200.9
		. 2.4.8 . < 1231 >
	- , , (-	17294-2:2016 . #3111 . #3500-Zn D

()

.1

ISO 23500-1	IDT	23500-1—2021 « - 1. »
ISO 23500-	IDT	23500-3—2021 « - 3. »
ISO 23500-4	IDT	23500-4—2021 « - 4. »

— :
- IDT — .

- [1] ISO 10359-1:1992. *Water quality — Determination of fluoride — Part 1: Electrochemical probe method for potable and tightly polluted water*
- [2] ISO17294-2:2016. *Water quality—Application of inductively coupled plasma mass spectrometry (ICP-MS) — Part 2: Determination of selected elements including uranium isotopes*
- [3] ISO 23500-2:2019. *Preparation and quality management of fluids for haemodialysis and related therapies — Part 2: Water treatment equipment for haemodialysis applications and related therapies*
- [4] RICE E.W., BAIRD A.B., EATON A.D. Standard Methods for the Examination of Water and Wastewater. 23rd Edition. American Public Health Association. American Water Works Association. Water Environment Federation. 2017
- [5] U.S. ENVIRONMENTAL PROTECTION AGENCY. Methods for the determination of metals in environmental samples. Supplement 1 (EPA-600-R-94-111). Cincinnati {Ohio} Environmental Monitoring Systems Laboratory
- [6] VAN DER LINDE K., UM B.T., RONDEEL J.M., ANTONISSEN L.P., DE JONG G.M. Improved bacteriological surveillance of haemodialysis fluids a comparison between Tryptic soy agar and Reasoner's 2A media. *Nephrol. Dial. Transplant.* 1999. 14 (10) pp. 2433—2437
- [7] REASONER D.J., GELDREICH E.E. A new medium for the enumeration and subculture of bacteria from potable water. *Appl. Environ. Microbiol.* 1985.49 pp. 1—7
- [8] MALTAIS J.B., MEYER K.B., FOSTER M.C. Comparison of techniques for culture of dialysis water and fluid. *Hemodial. tnL2017.* 21 pp. 197—205
- [9] MASAKANE I., TSUBAKIHARA Y., AKIBA T., WATANABE Y., ISEKI K. Bacteriological qualities of dialysis fluid in Japan as of 31 December 2006. *Ther. Apher. Dial.* 2008, 12 (6) pp. 457—463
- [10] DAWIDS S.G., VEJLSGAARD R. Bacteriological and clinical evaluation of different dialysate delivery systems. *Acta Med. Scand.* 1976. 199(3)pp. 151—155
- [11] FAVERO M.S., PETERSON N.J., BOYER K.M., CARSON LA., BOND W.W. Microbial contamination of renal dialysis systems and associated risks. *Trans. Amer. Soc. Artif. Int. Organs.* 1974. 20 pp. 175—183
- [12] FAVERO M.S., PETERSON N.J., CARSON LA., BOND W.W., HINDMAN S.H. Gram-negative water bacteria in hemodialysis systems. *Health Lab. Sc.* 1975, 12 (4) pp. 321—334
- [13] HINDMAN S.H., CARSON LA., PETERSON N.J., SCHONBERGER L.B., SOLANO J.T. Pyrogenic reactions during haemodialysis caused by extramural endotoxin. *Lancet.* 1975, 2 (7938) pp. 732—734
- [14] IZUHARA Y., MIYATAT., SAITO K., ISHIKAWA N., KAKUTA T., NANGAKU M., YOSHIDA H., SAITO A., KUROKAWA K., VAN YPERSELE de STRIHO C. Ultrapure dialysate decreases plasma pentosidine. a marker of 'carbonyl stress.'. *Am. J. Kidney Dis.* 2004.43 (6) pp. 1024—1029
- [15] JONES D.M., TOBIN B.M., HARLOW G.R., RALSTON A.J. Bacteriological studies of the modified Kiil dialyser. *BMJ.* 1970. 3 (5715) pp. 135—137
- [16] GAZENFELDT-GAZIT E., ELIAHOU H.E. Endotoxin antibodies in patients on maintenance hemodialysis. *Isr. J. Med. Sci.* 1969. 5 pp. 1032—1036
- [17] OUSEPH R., JONES S., DHANANJAYA N., WARD R.A. Use of ultrafiltered dialysate is associated with improvements in haemodialysis-associated morbidity in patients treated with reused dialysers. *Nephrol. Dial. Transplant.* 2007. 22 (8) pp. 2269—2275
- [18] VANHOLDER R., VAN HAECKE E., VEYS N., RINGOIR S. Endotoxin transfer through dialysis membranes small-versus large-pore membranes. *Nephrol. Dial. Transplant.* 1992. 7 (4) 333—339
- [19] LAUDE-SHARP M., CAROFF M., SIMARD L., PUSINERI C., KAZATCHKINE M.D., HAEFFNER-CAVA1LLON N. Induction of IL-1 during hemodialysis Transmembrane passage of intact endotoxin (LPS). *Kidney int.* 1990. 38 (6) pp. 1089—1094
- [20] EVANS R.C., HOLMES C.J. In vitro study of the transfer of cytokine-inducing substances across selected high-flux hemodialysis membranes. *Blood Purif.* 1991. 9 (2) pp. 92—101

- [21] URENAP.. HERBELIN A.. ZINGRAFF J.. LAIR .. MAN N.K.. DESCAMPS-LATSCHAB.. DRUEKE . Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis. *Nephrol. Dial. Transplant.* 1992. 7 (1)pp. 16—28
- [22] BOMMER J.. BECKER K.P.. URBASCHEK R. Potential transfer of endotoxin across high-flux polysulfone membranes. *J. Am. Soc. Nephrol.* 1996. 7 (6) pp. 883—888
- [23] SCHINDLER R.. CHR1ST-KOHLRAUSCH F.. FREI U.. SHALDON S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. *Clin. Nephrol.* 2003. 59 (6) pp. 447—454
- [24] WEBER V.. LINSBERGER I.. ROSSMANITH E., WEBER C.. FALKENHAGEN D. Pyrogen transfer across high- and low-flux hemodialysis membranes. *Artif. Organs.* 2004. 28 (2) pp. 210—217
- [25] SCHINDLER R.. BECK W.. DEPPISCH R.. AUSSIEKER M.. WILDE A.. GOHL H.. FREI U. Short bacterial DNA fragments Detection in dialysate and induction of cytokines. *J. Am. Soc. Nephrol.* 2004,15 (12) pp. 3207—3214
- [26] YAMAGAMI S.. ADACHI T.. SUGIMURA T.. WADA S.. KISHIMOTO T.. MAEKAWA M.. YOSHIMURA R.. NIWA M.. TERANO Y.. SHALDON S. Detection of endotoxin antibody in long-term dialysis patients. *Ini. J. Artif. Organs.* 1990. 13(4) pp. 205—210
- [27] TOKARS J.I.. ALTER M.J., FAVERO M.S. National surveillance of dialysis associated diseases in the United States. 1993. *ASAIOJ.* 1996. 42 (3) pp. 219—229
- [28] BERNICK J.J.. PORT F.K.. FAVERO M.S.. BROWN D.G. Bacterial and endotoxin permeability of hemodialysis membranes. *Kidney Int.* 1979. 16 (4) pp. 491—496
- [29] BOMMER J.. BECKER K.P.. URBASCHEK R.. RITZ E.. URBASCHEK B. No evidence for endotoxin transfer across high-flux polysulfone membranes. *Clin. Nephrol.* 1987. 27 (6) pp. 278—282
- [30] HASEGAWA T.. NAKAI S.. MASAKANE I.. WATANABE Y.. ISEKI K.. TSUBAKIHARA Y.. AKIZAWA T. Dialysis fluid endotoxin level and mortality in maintenance hemodialysis a nationwide cohort study. *Am J Kidney Dis.* 2015. 65 (6) pp. 899-904
- [31] KAWANISHI H.. MASAKANE I.. TOMO T. The new standard of fluids for hemodialysis in Japan. *Blood Purif.* 2009. 27 (Suppl 1)pp. 5—10
- [32] QUELLHORST E. Methods of hemodialysis. *Nieren- Hochdruckkr.* 1998. 27 pp.35—41
- [33] SCHINDLER R.. LONNEMANN G.. SCHAFFER J.. SHALDON S.. KOCH K.M.. KRAUTZIG S. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. *Nephron.* 1994. 68 (2) pp. 229—233
- [34] SCHIFFL H.. LANG S.M., STRATAKIS D.. FISCHER R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. *Nephrol. Dial. Transplant.* 2001. 16 (9) pp. 1863—1869
- [35] RAHMATI M.A.. HOMELP.. HOENICH N.A.. LEVIN R.. KAYSER G.A.. LEVIN N.W. The role of improved water quality on inflammatory markers in patients undergoing regular dialysis. *Ini. J. Artif. Organs.* 2004. 27 (8) pp. 723—727
- [36] HSU P.-Y., LIN C.-L.. YU C.C.. CHIEN C.C.. HSIAU T.G.. SUN . .. HUANG L.M.. YANG C.W. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients — A prospective cross-over study. *J. Nephrol.* 2004. 17 (5) pp. 693—700
- [37] ARIZONO K.. NOMURAK.. MOTOYAMAT.. MATSUOKA K.. MIYAZU R.. TAKESHITA H.. FUKUI H. Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. *Blood Purif.* 2004. 22 (Suppl 2) pp. 26—29
- [38] FURUYA R.. KUMAGAI H.. TAKAHASHI M.. SANO K.. HISHIDA A. Ultrapure dialysate reduces plasma levels of 2-microglobulin and pentosidine in hemodialysis patients. *Blood Purif.* 2005.23 (4) pp. 311—316
- [39] MATSUHASHI N.. YOSHIOKA T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients. *Nephron.* 2002. 92 (3) pp. 601—604
- [40] BAZ M.. DURAND C.. RAGON A. JABER K.. ANDRIEU D.. MERZOUK T., PURGUS R.. OLMER M.. REYNIER J.P.. BERLAND Y. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. *Ini. J. Artif. Organs.* 1991.14 (11) pp. 681—685
- [41] KLEOPHAS W.. HAASTERT B., BACKUS G.. HILGERS P. WESTHOFF A.. VAN ENDERT G. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. *Nephrol. Dial. Transplant.* 1998, 13 (12) pp. 3118—3125

- [42] SCHIFFL H., FISCHER R., LANG S.M., MANGEL A. Clinical manifestations of AB-amyloidosis. Effects of biocompatibility and flux. *Nephrol. Dial. Transplant.* 2000. 15 (6) pp. 640—845
- [43] MCKANE W., CHANDNA S.M., TATTERSALL J.E., GREENWOOD R.N., FARRINGTON K. identical decline of residual renal function in high-flux biocompatible hemodialysis and CARD. *Kidney Int.* 2002. 61 (1) pp. 256—265
- [44] SCHIFFL H., LANG S.M., FISCHER R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. *Nephrol. Dial. Transplant.* 2002. 17 (10) pp. 1614—1818
- [45] EUROPEAN RENAL ASSOCIATION — European Dialysis and Transplant Association. European Best Practice Guidelines for Haemodialysis. (Part I). Section IV Dialysis fluid purity. *Nephrol. Dial. Transplant.* 2002.17 (Suppl 7) pp. 45—62
- [46] LEDEBOI., NYSTRAND R. Defining the microbiological quality of dialysis fluid. *Artif. Organs.* 1999.23(1) pp. 37—43
- [47] LEYPOLDT J.K., SCHMIDT B., GURLAND H.J. Measurement of backfiltration rates during hemodialysis with highly permeable membranes. *Blood Purif.* 1991. 9 (2) pp. 74—84
- [48] PASS T., WRIGHT R., SHARP B., HARDING G.B. Culture of dialysis fluids on nutrient-rich media for short periods at elevated temperatures underestimates microbial contamination. *Blood Purif.* 1996.14 (2) pp. 136—145
- [49] SITTER T., BERGNER A., SCHIFFL H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. *Nephrol. Dial. Transplant.* 2000, 15 (8) pp. 1207—1211
- [50] KIDD E.E. Bacterial contamination of dialysing fluid of artificial kidney. *BMJ.* 1964, 1 (5387) pp. 880—882
- [51] HASHEMI SHAHRAKI A., TROVATO A., DROZ S., HAIDARIEH P., BORRONI E., MIRSAEIDI M., MANNINO R., HASHEMZADEH M., MARIOTTINI A., CIRILLO D.M., TORTOLI E. *Mycobacterium aquaticum* sp. nov., a rapidly growing species isolated from haemodialysis water. *Int J Syst Evol Microbiol.* 2017.67 (9) pp. 3279—3282
- [52] BOLAN G., REINGOLD A.L., CARSON L.A., SILCOX VA., WOODLEY C.L., HAYES P.S., HIGHTOWER A.W., MCFARLAND L., BROWN J.W. 3rd., PETERSEN N.J. Infections with *Mycobacterium chelonae* in patients receiving dialysis and using reprocessed dialyzers. *J. Infect. Dis.* 1985. 152 (5) pp. 1013—1019
- [53] LOWRY P.W., BECK-SAGUE C.M., BLAND LA., AGUERO SM., ARDUINO M.J., MINUTH A.N., MURRAY RA., SWENSON J.M., JARVIS W.R. *Mycobacterium chelonae* infection among patients receiving high-flux dialysis in a hemodialysis clinic in California. *J. Infect. Dis.* 1990.161 (1) pp. 85—90
- [54] ISO 7890-3:1988. *Water quality—Determination of nitrate — Part3: Spectrometric method using sulfosalicylic acid*
- [55] EPA300.7:1986. *Quality Criteria for Water*
- [56] EPA 200.9:1994. *Determination of Trace Elements by Stabilized Temperature Graphite Furnace Atomic Absorption*

628.1.038:616.61-78:006.354

11.040.60

⋮ , , , ,

• •
• •
• •
• •

22.10.2021 01.11.2021 6 *84 .
• • .2.32. .< • .2.10.

,
»